Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplant for B-Cell Lymphomas in the Era of Novel Cellular Therapies: Experience from a Tertiary Canadian Center

Mathias Castonguay, Jean-Sébastien Claveau, Jean Roy, Sandra Cohen, Sylvie Lachance, Imran Ahmad, Nadia M. Bambace, Lea Bernard, Jean-Sebastien Delisle, Thomas L. Kiss, Isabelle Fleury, Luigina Mollica, Denis-Claude Roy, Guy Sauvageau, Olivier Veilleux

Blood (2024) 144 (Supplement 1): 7446.

https://doi.org/10.1182/blood-2024-210718

Published: 2024

Journal Articles

UM171 Cord Blood Transplantation for TP53 Mutated and EVI1 Rearranged Myelodysplasia/Acute Myeloid Leukemia

Sandra Cohen, Nadia M. Bambace, Lea Bernard, Imran Ahmad, Jean Roy, Sylvie Lachance, Jean-Sebastien Delisle, Thomas L. Kiss, Denis-Claude Roy, Olivier Veilleux, Guy Sauvageau

Blood (2024) 144 (Supplement 1): 1502.

https://doi.org/10.1182/blood-2024-211972

Published: 2024

Journal Articles

Long Term Follow up of UM171 Expanded Cord Blood Transplantation Patients Does Not Reveal Any Late Toxicity

Sandra Cohen, Nadia M. Bambace, Lea Bernard, Imran Ahmad, Jean Roy, Sylvie Lachance, Jean-Sebastien Delisle, Thomas L. Kiss, Denis-Claude Roy, Olivier Veilleux, Guy Sauvageau

Blood (2024) 144 (Supplement 1): 4916.

https://doi.org/10.1182/blood-2024-194132

Published: 2024

Journal Articles

Ex Vivo Generation and Infusion of Anti-Minor Histocompatibility Antigen Expanded T Cells for Patients Who Relapse after Allogeneic HLA-Matched Stem Cell Transplantation

Blood (2022) 140 (Supplement 1): 1601–1603.

https://doi.org/10.1182/blood-2022-170147

Published: 2022

Journal Articles

The EBMT Disease Risk Stratification System (DRSS) Allows Prediction of Relapse after Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome

Yasmine Kadri, Michelle Phan, Nadia Bambace, Léa Bernard, Sandra Cohen, Jean-Sébastien Delisle, Thomas L. Kiss, Sylvia Lachance, Denis-Claude Roy, Jean Roy, Guy Sauvageau, Olivier Veilleux, Imran Ahmad

Blood (2022) 140 (Supplement 1): 7759–7760.

https://doi.org/10.1182/blood-2022-157107

Published: 2022

Journal Articles

Improved Outcomes of UM171-Expanded Cord Blood Transplantation Compared with Other Graft Sources: Real World Evidence

Sandra Cohen, Nadia M. Bambace, Imran Ahmad, Linda J. Burns, Jean Roy, Silvy Lachance, Léa Bernard, Jean-Sébastien Delisle, Denis-Claude Roy, Thomas L. Kiss, Olivier Veilleux, Mei-Jie Zhang, Xiao-Ying Tang, Guy Sauvageau

Blood (2022) 140 (Supplement 1): 1610–1612.

https://doi.org/10.1182/blood-2022-160417

Published: 2022

Journal Articles

UM171-Expanded Cord Blood Transplants Support Robust T-Cell Reconstitution with Low Rates of Severe Infections

Blood (2020) 136 (Supplement 1): 36–37.

https://doi.org/10.1182/blood-2020-139598

Published: 2020

Journal Articles

UM171 Modified Cord Blood Achieves Excellent Survival and Disease Control after 2 Years of Follow-up in High and Very High Risk Malignancies

Sandra Cohen, MD FRCP(C), Jean Roy, MD, Jean-Sébastien Delisle, MD PhD, Nadia M. Bambace, MD, Imran Ahmad, MD, Silvy Lachance, MD FRCP, Léa Bernard, MD, Frederic Barabe, MD, Thomas L. Kiss, MD, Lambert Busque, MD, Denis-Claude Roy, MD, Filippo Milano, MD PhD, Guy Sauvageau, MD PhD

Blood (2019) 134 (Supplement_1): 3245.

https://doi.org/10.1182/blood-2019-121698

Published: 2019

Journal Articles

Reduced Intensity Conditioned Sibling Transplantation Versus No Transplant in Intermediate or High Risk Acute Myeloid Leukemia: A Prospective Multi-Center Study in Patients 50-70 Years in First Complete Remission and with at Least One Potential Sibling Donor ( ClinTrialGov 00342316 )

Mats Brune, MD PhD, Thomas L. Kiss, MD, Elisabeth Wallhult, RN, Harald Anderson, PhD, Robert Delage, MD, Jürgen Finke, MD, Josee Hebert, MD, Martin Höglund, MD PhD, Ain Kaare, MD, Vladimir Lazarevic, MD PhD, Malin Nicklasson, MSc, Kari Remes, MD PhD, David Ritchie, MBChB, PhD FRACP, FRCPA, Mitchell Sabloff, MD, Ruth Spearing, MD, Alexandros Spyridonidis, MD PhD, Jeffrey Szer, MBBS, Per Ljungman, MD PhD

Blood (2018) 132 (Supplement 1): 205.

https://doi.org/10.1182/blood-2018-99-110260

Published: 2018

Journal Articles

Single UM171 Expanded Cord Blood Permits Transplantation of Better HLA Matched Cords with Excellent Gvhd Relapse Free Survival

Blood (2018) 132 (Supplement 1): 4658.

https://doi.org/10.1182/blood-2018-99-110188

Published: 2018

Journal Articles

Minimal Residual Disease Evaluation Using 8-Color Flow Cytometry Predicts Risk of Relapse in High-Risk and/or Young Myeloma Patients Who Receive Bortezomib Consolidation after Frontline Tandem Transplantation

Richard Leblanc, MD FRCPC, Imran Ahmad, MD MPH, Rafik Terra, PhD, Séverine Landais, PhD, Céline Nkoue, MD, Michael Sebag, MD PhD, Émilie Lemieux Blanchard, MD FRCPC, Nadia M. Bambace, MD, Léa Bernard, MD, Sandra Cohen, MD FRCP(C), Jean-Sébastien Delisle, MD PhD, Thomas L. Kiss, MD, Silvy Lachance, MD FRCP, Denis-Claude Roy, MD, Guy Sauvageau, MD, PhD, Jean Roy, MD

Blood (2018) 132 (Supplement 1): 4666.

https://doi.org/10.1182/blood-2018-99-112313

Published: 2018

Journal Articles

Impact of Carmustine (BCNU) Substitution for Bendamustine in the Conditioning Regimen Prior to Autologous Hematopoietic Cell Transplantation for the Treatment of Lymphoma

Josie-Anne Boisjoly, MD, Philippe Bouchard, BPharm, Sandra Cohen, MD FRCP(C), Imran Ahmad, MD, Nadia M. Bambace, MD, Léa Bernard, MD, Jean-Sébastien Delisle, MD PhD, Thomas L Kiss, MD, Denis-Claude Roy, MD, Guy Sauvageau, MD, PhD, Jean Roy, MD, Silvy Lachance, MDFRCPC

Blood (2017) 130 (Supplement 1): 2022.

https://doi.org/10.1182/blood.V130.Suppl_1.2022.2022

Published: 2017

Journal Articles

Single UM171 Expanded Cord Blood Transplant Is Feasible, Safe, and Permits Transplantation of Better HLA Matched Cords with Very Low Transplant Related Mortality

Sandra Cohen, MD, Jean Roy, MD, Silvy Lachance, MDFRCPC, Anne Marinier, PhD, Denis-Claude Roy, MD, Jean-Sébastien Delisle, MD PhD, Lambert Busque, MD, Pierre Caudrelier, MD, Fannie Larochelle, Philippe Bouchard, BPharm, Jean Roy, MD, Nadia M. Bambace, MD, Léa Bernard, MD, Thomas L Kiss, MD, Sébastien Lemieux, PhD, Peter W. Zandstra, PhD, Guy Sauvageau, MD, PhD

Blood (2017) 130 (Supplement 1): 658.

https://doi.org/10.1182/blood.V130.Suppl_1.658.658

Published: 2017

Journal Articles

Comparison of Outcomes of Elderly Patients with Acute Myeloid Leukemia (AML) in CR1 Receiving Reduced Intensity Allogeneic Stem Cell Transplantation (RICT) from Matched Sibling (MSD) or Unrelated Donors (URD)

Thomas L Kiss, MD, Elisabeth Wallhult, RN, Harald Anderson, PhD, Robert Delage, MD, Jürgen Finke, MD, Tobias Gedde-Dahl, MD PhD, Vladimir Lj Lazarevic, MD PhD, Kari Remes, MD PhD, David Ritchie, MD PhD, Mitchell Sabloff, MD, Alexandros Spyridonidis, MD PhD, Per Ljungman, Mats Brune, MD

Blood (2017) 130 (Supplement 1): 4557.

https://doi.org/10.1182/blood.V130.Suppl_1.4557.4557

Published: 2017

Journal Articles

Favourable Overall Survival with Myeloablative Allogeneic Stem Cell Transplantation for Follicular Lymphoma.

John Kuruvilla, MD, Qikun Bao, Erica Messner, Vikas Gupta, MD, Thomas L. Kiss, MD, Jeffrey H. Lipton, MD PhD, Mark D. Minden, MD PhD, Hans A. Messner, MD PhD

Blood (2006) 108 (11): 3005.

https://doi.org/10.1182/blood.V108.11.3005.3005

Published: 2006

Journal Articles

Long-Term Follow-Up of Allogeneic Stem Cell Transplantation for Chronic Lymphocytic Leukemia.

John Kuruvilla, MD, Qikun Bao, Mira Goldberg, Vikas Gupta, MD, Thomas L. Kiss, MD, Jeffrey H. Lipton, MD, PhD, Mark D. Minden, MD, Hans A. Messner, MD, PhD

Blood (2006) 108 (11): 3032.

https://doi.org/10.1182/blood.V108.11.3032.3032

Published: 2006

NARROW

Allogeneic Hematopoietic Stem Cell Transplant for B-Cell Lymphomas in the Era of Novel Cellular Therapies: Experience from a Tertiary Canadian Center

UM171 Cord Blood Transplantation for TP53 Mutated and EVI1 Rearranged Myelodysplasia/Acute Myeloid Leukemia

Long Term Follow up of UM171 Expanded Cord Blood Transplantation Patients Does Not Reveal Any Late Toxicity

Ex Vivo Generation and Infusion of Anti-Minor Histocompatibility Antigen Expanded T Cells for Patients Who Relapse after Allogeneic HLA-Matched Stem Cell Transplantation

The EBMT Disease Risk Stratification System (DRSS) Allows Prediction of Relapse after Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome

Improved Outcomes of UM171-Expanded Cord Blood Transplantation Compared with Other Graft Sources: Real World Evidence

UM171-Expanded Cord Blood Transplants Support Robust T-Cell Reconstitution with Low Rates of Severe Infections

UM171 Modified Cord Blood Achieves Excellent Survival and Disease Control after 2 Years of Follow-up in High and Very High Risk Malignancies

Reduced Intensity Conditioned Sibling Transplantation Versus No Transplant in Intermediate or High Risk Acute Myeloid Leukemia: A Prospective Multi-Center Study in Patients 50-70 Years in First Complete Remission and with at Least One Potential Sibling Donor ( ClinTrialGov 00342316 )

Single UM171 Expanded Cord Blood Permits Transplantation of Better HLA Matched Cords with Excellent Gvhd Relapse Free Survival

Minimal Residual Disease Evaluation Using 8-Color Flow Cytometry Predicts Risk of Relapse in High-Risk and/or Young Myeloma Patients Who Receive Bortezomib Consolidation after Frontline Tandem Transplantation

Impact of Carmustine (BCNU) Substitution for Bendamustine in the Conditioning Regimen Prior to Autologous Hematopoietic Cell Transplantation for the Treatment of Lymphoma

Single UM171 Expanded Cord Blood Transplant Is Feasible, Safe, and Permits Transplantation of Better HLA Matched Cords with Very Low Transplant Related Mortality

Comparison of Outcomes of Elderly Patients with Acute Myeloid Leukemia (AML) in CR1 Receiving Reduced Intensity Allogeneic Stem Cell Transplantation (RICT) from Matched Sibling (MSD) or Unrelated Donors (URD)

Favourable Overall Survival with Myeloablative Allogeneic Stem Cell Transplantation for Follicular Lymphoma.

Long-Term Follow-Up of Allogeneic Stem Cell Transplantation for Chronic Lymphocytic Leukemia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only